Amgen (TSX:AMGN) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:AMGN Amgen Inc TSX:AMGN
71 GF Score
Price C$30.43
GF Value C$27.13
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Amgen  (TSX:AMGN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Amgen Cyclically Adjusted PB Ratio Related Terms


Amgen Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted PB Ratio Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.15 8.54 9.82 9.65 13.49

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.81 11.20 13.49 14.77 15.58

TSX:AMGN vs GILD, PFE, BMY: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted PB Ratio falls into.


TSX:AMGN
71GF Score
Amgen Inc TSX:AMGN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Amgen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Amgen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.66/333.9520*333.9520
=1.660

Current CPI (Jun. 2026) = 333.9520.

Amgen Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.981 241.428 4.123
201612 2.972 241.432 4.111
201703 3.067 243.801 4.201
201706 3.177 244.955 4.331
201709 2.998 246.819 4.056
201712 2.456 246.524 3.327
201803 1.669 249.554 2.233
201806 1.660 251.989 2.200
201809 1.607 252.439 2.126
201812 1.468 251.233 1.951
201903 1.297 254.202 1.704
201906 1.311 256.143 1.709
201909 1.336 256.759 1.738
201912 1.186 256.974 1.541
202003 1.239 258.115 1.603
202006 1.356 257.797 1.757
202009 1.368 260.280 1.755
202012 1.147 260.474 1.471
202103 1.122 264.877 1.415
202106 0.974 271.696 1.197
202109 1.014 274.310 1.234
202112 0.845 278.802 1.012
202203 0.119 287.504 0.138
202206 0.319 296.311 0.360
202209 0.503 296.808 0.566
202212 0.513 296.797 0.577
202303 0.754 301.836 0.834
202306 0.927 305.109 1.015
202309 1.066 307.789 1.157
202312 0.860 306.746 0.936
202403 0.698 312.332 0.746
202406 0.832 314.175 0.884
202409 1.044 315.301 1.106
202412 0.858 315.605 0.908
202503 0.912 319.799 0.952
202506 1.038 322.561 1.075
202509 1.360 324.800 1.398
202512 1.220 324.054 1.257
202603 1.286 330.213 1.301
202606 1.660 333.952 1.660

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Amgen (TSX:AMGN) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of C$30.43 is trading 12.2% above its estimated GF Value™ of C$27.13. GuruFocus considers Amgen to be Modestly Overvalued.

Key valuation signals for TSX:AMGN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: C$27.13 vs. price of C$30.43 (12.2% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the TSX:AMGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
71GF Score

Get the complete analysis for TSX:AMGN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$30.43
Price
C$27.13
GF Value